

SINGAPORE INVESTOR BRIEFING – VENUE UPDATE

MELBOURNE, Australia, 9 April 2026: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, is pleased to invite investors to attend an interactive lunch briefing in Singapore this month.

CEO & Managing Director, Dr Nina Webster will present an update on the Company's global ACTION3 Phase 3 clinical trial in focal segmental glomerulosclerosis (FSGS) kidney disease, outline the commercial partnering status of DMX-200, and discuss Dimerix' growth strategy. There will be a Q&A opportunity at the end of the presentation.

Event details

Date: Monday, 20 April 2026

Time: 12:15pm for a 12:30pm start (SGT)

Location: The Fullerton Hotel (Inland Revenue Room) - 1 Fullerton Square, Singapore

Event Details: During the lunch, Dimerix CEO & Managing Director, Dr Nina Webster will present the Dimerix opportunity to investors. Also during the lunch, Dr Daniel Tillett, CEO and Managing Director of Racura Oncology (ASX: RAC) will present the Racura opportunity.

Catering: Lunch will be provided during the briefing. Please advise of any dietary requirements at the time of your RSVP.

RSVP: anna.cvijetic@irdepartment.com.au by Tuesday, 14 April 2026.

Places are strictly limited, so please RSVP soon to secure your spot!

The Dimerix team looks forward to seeing all those who can make it along to the Singapore briefing.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Jane Lowe
IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au

Follow us on [LinkedIn](#) and [X](#)

Authorised for lodgement by the Board of the Company

—END—

About Dimerix Limited

DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2045, in addition to Orphan Drug Designation granted in the United States, Europe, UK and Japan¹. For more information, please visit the company's website at www.dimerix.com and follow on [X](#) and [LinkedIn](#).

About FSGS

FSGS is a rare, serious kidney disorder characterised by progressive scarring (sclerosis) in parts of the glomeruli—the kidney's filtering units. This scarring leads to proteinuria, progressive loss of kidney function, and often end-stage renal disease. FSGS is increasingly understood to have an inflammatory component, with monocyte and macrophage activation contributing to glomerular injury. In the United States, more than 40,000 people are estimated to be living with FSGS, including both adults and children.² There are no therapies specifically approved for FSGS in the U.S., and disease management relies on non-specific immunosuppressive and supportive therapies. In patients with progressive or treatment-resistant FSGS, the average time from diagnosis to end-stage kidney disease can be as short as five years. Even among those who undergo kidney transplantation, disease recurrence occurs in up to 60% of cases,³ underscoring the urgent need for new, disease-modifying treatments.

About FSGS Phase 3 Study

The ACTION3 Phase 3 study is a pivotal Phase 3, multi-centre, randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of a blood pressure medication known as an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients are then randomised to receive either DMX-200 (120 mg capsule, twice daily) or placebo for a 2-year treatment period.

The single Phase 3 trial in FSGS patients is designed to capture evidence of proteinuria reduction and kidney function (eGFR slope) during the trial, aimed at generating sufficient evidence to support marketing approval.

Dimerix Forward Looking Statement

This release includes forward-looking statements that are subject to risks and uncertainties. Although management believes that the expectations reflected in the forward-looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, including but not limited to those factors outlined in the most recent Dimerix Limited Annual Report.

References

- 1 ASX releases: 14 December 2015, 21 November 2018, 07 June 2021, 30 September 2025
- 2 Nephcure FSGS Facts (<https://nephcure.org/>)
- 3 *Front. Immunol.*, (July 2019) | <https://doi.org/10.3389/fimmu.2019.01669>